Jakubowiak studies john rocker presented the bobby cox autographed baseball observes following results:* ORR was 97 percent, with 22 percent of patients achieving a complete response(CR)/near complete response (nCR). * Grade 3 and 4 toxicities included pneumonia/infections (7 patients),neutropenia (4 patients), thrombocytopenia (3 patients), fatigue (2 patients),deep vein thrombosis/pulmonary embolism (2 patients) and sensory neuropathy (1patient)."In this study, the data show that this four-drug combination was well toleratedin patients with newly diagnosed multiple myeloma, and appeared to be highlyactive," said Jakubowiak. "We are hopeful that these initial results willtranslate into better outcomes for patients with more follow-up." Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction therapyin newly diagnosed multiple myeloma: Results of an interim analysis of theGerman DSMM XIa trialIn a Phase I/II study, researchers explored the effectiveness of VELCADE,cyclophosphamide and dexamethasone as induction therapy in preparation forautologous stem cell transplant (ASCT) in 200 patients with a mean age of 52.4years. The maximum tolerated dose of cyclophosphamide was 900 mg/m2, andpatients in the Phase II portion of the trial received three cycles of inductionwith 1.3 mg/m2 of VELCADE on days 1, 4, 8 and 11; 40 mg/d of dexamethasone ondays 1, 2, 4, 5, 8, 9, 11 and 12; and 900 mg/m2 of IV cyclophosphamide on day 1.Stefan Knop, M.D., University Hospital of Wuerzberg, Germany, presented thefollowing results:* ORR was 84 percent, and 12.5 percent of patients achieved CR.

* ORRs in cytogenetic subgroups were as follows:* 81.8 percent in patients with 13q-deletion * 93.8 percent in patients with t(4;14) * 70 percent in patients with 17p-deletion.* Adverse events included grade 3 or higher neutropenia in 6.5 percent ofpatients and grade 3 neuropathy in 3.5 percent, and mortality rate duringinduction was 1 percent."These preliminary results suggest that this is an effective induction regimenfor younger patients, regardless of their cytogenetic risk factors," said Knop baseball ticket . About Multiple MyelomaMultiple myeloma is the second most common hematologic malignancy and althoughthe disease is predominantly a cancer of the elderly (the median age of onset is70 years), recent statistics indicate both increasing incidence and younger ageof onset bobby cox signed baseball . In the U.S., more than 50,000 individuals have MM and 20,000 new casesare diagnosed each year baseball . Worldwide there are approximately 74,000 new cases andover 45,000 deaths annually hotel turner field . About VELCADEVELCADE is co-developed by Millennium Pharmaceuticals, Inc. and Johnson &Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsiblefor commercialization of VELCADE in the U.S., Janssen-Cilag is responsible forcommercialization in Europe and the rest of the world Janssen PharmaceuticalK.K is responsible for commercialization in Japan VELCADE is approved in morethan 87 countries worldwide.

Important Safety InformationIn the U.S., VELCADE is indicated for the treatment of patients with multiplemyeloma bobby cox . VELCADE also is indicated for the treatment of patients with mantlecell lymphoma who have received at least one prior therapy world baseball series . VELCADE iscontraindicated in patients with hypersensitivity to bortezomib, boron ormannitol baseball managers . VELCADE should be administered under the supervision of a physicianexperienced in the use of antineoplastic therapy bobby cox autographed baseball . Risks associated with VELCADE therapy include new or worsening peripheralneuropathy, hypotension throughout therapy, cardiac and pulmonary disorders,reversible posterior leukoencephalopathy syndrome, gastrointestinal adverseevents, thrombocytopenia, neutropenia, tumor lysis syndrome and hepatic events.Women of childbearing potential should avoid becoming pregnant while beingtreated with VELCADE. Nursing mothers are advised not to breastfeed whilereceiving VELCADE. Cases of severe sensory and motor peripheral neuropathy havebeen reported.

The long-term outcome of peripheral neuropathy has not beenstudied in mantle cell lymphoma world series 1992 . Acute development or exacerbation of congestiveheart failure, and new onset of decreased left ventricular ejection fraction hasbeen reported, including reports in patients with no risk factors for decreasedleft ventricular ejection fraction bobby cox signed baseball . There have been reports of acute diffuseinfiltrative pulmonary disease of unknown etiology such as pneumonitis,interstitial pneumonia, lung infiltration and Acute Respiratory DistressSyndrome in patients receiving VELCADE baseball . Some of these events have been fatal.There have been reports of Reversible Posterior Leukoencephalopathy Syndrome(RPLS) in patients receiving VELCADE .